Drugs / Iparomlimab and tuvonralimab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07847359 | Oct 2026 → Dec 2028 expected | cutaneous melanoma | Sun Yat-sen University | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iparomlimab and tuvonralimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07847359 ↗ |
| Known as | QL1706 | “Iparomlimab and tuvonralimab (QL1706; Qilu Pharmaceutical Co., Ltd., Jinan, China) is a dual PD-1/CTLA-4 combination antibody.” NCT07847359 ↗ |
| Modality | Protein / enzyme biologic | “is a dual PD-1/CTLA-4 combination antibody.” NCT07847359 ↗ |
| Route | Other | “During the combination phase, QL1706 is administered by hepatic arterial infusion.” NCT07847359 ↗ |